Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 86 people in total — 39 in a group receiving a sirolimus (SRL) based medication regimen and 47 in a group receiving a calcineurin inhibitor (CNI) based regimen. Both groups were already transplant recipients who had previously developed non-melanoma skin cancers (NMSCs) — a category that includes two common skin cancer types: squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). The trial was measuring whether the type of anti-rejection medication a person took was linked to differences in how often new skin cancers appeared. Around half of participants in each group did not complete the study (19 in the SRL group and 23 in the CNI group). The reported data shows that the main thing being tracked — the rate of new, biopsy-confirmed (meaning confirmed by a tissue sample test) skin cancer lesions per person per year — was recorded as 1.31 in the sirolimus group and 2.48 in the CNI group. For the secondary measures, the reported data shows the average number of days until a first new skin cancer lesion was confirmed was 380 days in the sirolimus group and 163 days in the CNI group. The reported data also shows that 17 out of 39 participants in the sirolimus group had no new lesions during the study, compared with 9 out of 47 in the CNI group. The rate of skin cancers that came back at a previously treated spot was reported as 0.107 lesions per person per year in the sirolimus group and 0.134 in the CNI group. The breakdown between SCC and BCC lesion types was broadly similar between the two groups (around 67–69% SCC and 31–33% BCC). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 22420843) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Kidney Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- You received a kidney transplant at least 1 year ago
- Your transplanted kidney is working reasonably well, with good kidney function levels and only a small amount of protein in your urine (confirm with trial site for specific measurements)
- You are currently taking a stable combination of anti-rejection medications based on either cyclosporine or tacrolimus
- You have been diagnosed with a non-melanoma skin cancer (such as basal cell or squamous cell carcinoma) within the last 3 years
Who may not be able to join:
- You have been diagnosed with any other type of cancer (other than non-melanoma skin cancer) within the last 3 years
- Your non-melanoma skin cancer has spread to other parts of your body, or you have had more than 20 non-melanoma skin cancer lesions in the past 12 months
- You have received more than one organ transplant
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.